FDA
-
-
-
-
-
-
-
Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021
-
-
-
-
-
-
-
Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update
-
-
-
-
-
-
-
Dicerna Pharma (DRNA) Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469
-
-
-
-
-
-
-
Dicerna Announces Full Year 2020 Financial Results and Provides a Business Update
-
-
-
-
-
-
-
Dicerna (DRNA) Presents Positive New Interim Data From PHYOX3 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria
-
-
-
-
-
-
-
Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs
-
-
-
-
-
-
-
Dicerna™ Announces Third Quarter 2019 Financial Results and Reports Development Programs Progress
-
322,094 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

